血浆miRNA作为子宫内膜异位症的生物标志物
研究通过小RNA测序在发现队列(120例,对照38例,内异症82例)中筛选血浆miRNA并构建诊断模型,在独立验证队列(90例,对照30例,内异症60例)中验证;仅轻微-轻度内异症模型(hsa-miR-125b-5p、hsa-miR-28-5p、hsa-miR-29a-3p)在验证中AUC=60%,灵敏度78%、特异度37%,miRNA诊断模型未通过独立验证。
要点
- 基于小RNA测序发现42个差异表达miRNA,RT-qPCR确认41个,构建3个诊断模型。
- 仅轻微-轻度内异症模型在独立验证中有高于随机水平的诊断效能(AUC=60%)。
- 该模型灵敏度78%、特异度37%,作者认为miRNA作为不孕女性内异症临床标志物的潜力存疑。
核心结论
- miRNA-based诊断模型未通过独立验证。
- 研究支持某些miRNA与子宫内膜异位症可能存在生物学联系,但这些miRNA在不孕女性中作为临床有用生物标志物的潜力存疑。
- 需要在大规模、描述良好的患者队列中,采用严格的miRNA表达分析方法、足够的统计效能和独立验证步骤,来回答miRNA能否作为子宫内膜异位症诊断标志物的问题。
研究设计与样本
- 通过小RNA测序进行全基因组miRNA表达谱分析,以识别在子宫内膜异位症患者与非患者之间具有区分潜力的血浆miRNA集。
- 通过RT-qPCR确认该miRNA集的表达,并使用多变量逻辑回归与逐步特征选择构建诊断模型。
- 在独立患者队列中对模型进行验证测试。
- 所有患者血浆来自Leuven子宫内膜异位症卓越中心生物样本库。
- 生物标志物发现和模型开发在120例发现队列(对照=38,内异症=82)中进行,模型在90例独立队列(对照=30,内异症=60)中验证。
主要发现
- 基于全基因组miRNA表达谱分析,识别出42个在子宫内膜异位症患者与非患者之间具有区分力的miRNA。
- 41个miRNA的表达通过RT-qPCR确认,并构建了3个诊断模型。
- 仅轻微-轻度子宫内膜异位症模型(模型2:hsa-miR-125b-5p、hsa-miR-28-5p和hsa-miR-29a-3p)在独立验证中具有高于随机性能的诊断力(AUC=60%),灵敏度可接受(78%)但特异度差(37%)。
关键数值与推荐
- 轻微-轻度子宫内膜异位症模型(模型2:hsa-miR-125b-5p、hsa-miR-28-5p和hsa-miR-29a-3p)在独立验证中AUC=60%,灵敏度78%,特异度37%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 诊断模型在两个来自单一三级子宫内膜异位症中心的患者队列中构建并验证。
- 需要在来自多个子宫内膜异位症中心的大规模队列中进一步验证测试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can plasma miRNAs be used for the non-invasive diagnosis of endometriosis in infertile women? SUMMARY ANSWER: miRNA-based diagnostic models for endometriosis failed the test of independent validation. WHAT IS KNOWN ALREADY: Circulating miRNAs have been described to be differentially expressed in patients with endometriosis compared with women without endometriosis, suggesting that they could be used for the non-invasive diagnosis of endometriosis. However, these studies have shown limited consistency or conflicting results, and no miRNA-based diagnostic test has been validated in an independent patient cohort. STUDY DESIGN, SIZE, DURATION: We performed genome-wide miRNA expression profiling by small RNA sequencing to identify a set of plasma miRNAs with discriminative potential between patients with and without endometriosis. Expression of this set of miRNAs was confirmed by RT-qPCR. Diagnostic models were built using multivariate logistic regression with stepwise feature selection. In a final step, the models were tested for validation in an independent patient cohort. PARTICIPANTS/MATERIALS, SETTINGS, METHODS: Plasma of all patients was available in the biobank of the Leuven Endometriosis Centre of Excellence. Biomarker discovery and model development were performed in a discovery cohort of 120 patients (controls = 38, endometriosis = 82), and models were tested for validation in an independent cohort of 90 patients (controls = 30, endometriosis = 60). RNA was extracted with the miRNeasy Plasma Kit. Genome-wide miRNA expression analysis was done by small RNA sequencing using the NEBNext small RNA library prep kit and the NextSeq 500 System. cDNA synthesis and qPCR were performed using the Qiagen miScript technology. MAIN RESULTS AND THE ROLE OF CHANCE: We identified a set of 42 miRNAs with discriminative power between patients with and without endometriosis based on genome-wide miRNA expression profiling. Expression of 41 miRNAs was confirmed by RT-qPCR, and 3 diagnostic models were built. Only the model for minimal-mild endometriosis (Model 2: hsa-miR-125b-5p, hsa-miR-28-5p and hsa-miR-29a-3p) had diagnostic power above chance performance in the independent validation (AUC = 60%) with an acceptable sensitivity (78%) but poor specificity (37%). LIMITATIONS, REASONS FOR CAUTION: The diagnostic models were built and tested for validation in two patient cohorts from a single tertiary endometriosis centre. Further validation tests in large cohorts with patients from multiple endometriosis centres are needed. WIDER IMPLICATION OF THE FINDINGS: Our study supports a possible biological link between certain miRNAs and endometriosis, but the potential of these miRNAs as clinically useful biomarkers is questionable in women with infertility. Large studies in well-described patient cohorts, with rigorous methodology for miRNA expression analysis, sufficient statistical power and an independent validation step, are necessary to answer the question of whether miRNAs can be used as diagnostics markers for endometriosis. STUDY FUNDING/COMPETING INTEREST(S): The project was funded by a grant from the Research Foundation - Flanders (FWO). A.V., D.F.O. and D.P. are PhD fellows from the FWO. T.D. is vice president and Head of Global Medical Affairs Fertility, Research and Development, Merck KGaA, Darmstadt, Germany. He is also a professor in Reproductive Medicine and Biology at the Department of Development and Regeneration, Group Biomedical Sciences, KU Leuven (University of Leuven), Belgium and an adjunct professor at the Department of Obstetrics and Gynecology in the University of Yale, New Haven, USA. Neither his corporate role nor his academic roles represent a conflict of interest with respect to the work done by him for this study. The other co-authors have no conflict of interest. TRIAL REGISTRATION NUMBER: Not applicable.
引用
- Vanhie A, O D, Peterse D, et al. Plasma miRNAs as biomarkers for endometriosis. Hum Reprod. 2019. PMID: 31411334. doi:10.1093/humrep/dez116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。